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Summary. The blood vessel wall has a number of self-
healing properties, enabling it to minimize blood loss and
prevent or overcome infections in the event of vascular
trauma. Endothelial cells prepackage a cocktail of hemo-
static, inflammatory and angiogenic mediators in their
unique secretory organelles, the Weibel–Palade bodies
(WPBs), which can be immediately released on demand.
Secretion of their contents into the vascular lumen
through a process called exocytosis enables the endothe-
lium to actively participate in the arrest of bleeding and
to slow down and direct leukocytes to areas of inflamma-
tion. Owing to their remarkable elongated morphology
and their secretory contents, which span the entire size
spectrum of small chemokines all the way up to ultralarge
von Willebrand factor multimers, WPBs constitute an
ideal model system for studying the molecular mecha-
nisms of secretory organelle biogenesis, exocytosis, and
content expulsion. Recent studies have now shown that,
during exocytosis, WPBs can undergo several distinct
modes of fusion, and can utilize fundamentally different
mechanisms to expel their contents. In this article, we dis-
cuss recent advances in our understanding of the compo-
sition of the WPB exocytotic machinery and how,
because of its configuration, it is able to support WPB
release in its various forms.
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Weibel–Palade bodies: secretory organelles of the
endothelium
The main cargo of Weibel–Palade bodies (WPBs) is von
Willebrand factor (VWF), which is a large multimeric
adhesive protein that mediates platelet adhesion to the
endothelium and to the subendothelial matrix [1,2]. VWF
also acts as a chaperone for coagulation factor VIII in
plasma, and prevents its premature clearance, which is
critical for the maintenance of normal circulating FVIII
levels. VWF undergoes a complex series of post-transla-
tional modifications, including glycosylation, multimeriza-
tion, and proteolytic processing, and is the driving force
behind the formation of WPBs. Mutations in VWF that
affect its synthesis or processing and subsequent storage
in WPBs constitute the basis of von Willebrand disease
(VWD), which is the most common inherited bleeding
disorder, and is caused by quantitative or qualitative
defects in VWF. The topics of VWF biosynthesis, WPB
formation and VWD have been extensively covered in a
number of excellent reviews [3–5], and are therefore not
included in this review.
Alongside VWF, a considerable number of inflamma-
tory and angiogenic mediators are copackaged into WPBs
(Fig. 1C) [6,7]. Their simultaneous release from this vas-
cular emergency package will also direct leukocytes to
sites of inflammation and promote vessel repair. To tailor
its secretory response to the prevailing vascular condition,
the endothelium continuously transduces cues from the
local microenvironment into dynamic control over the
content of WPBs by selectively including or excluding cer-
tain cargoes. Conditions that mimic laminar flow lead to
a reduced angiopoietin-2 (Ang-2) content in WPBs [8].
Exposure to proinflammatory cytokines leads to upregu-
lation of chemokines such as interleukin (IL)-8, monocyte
chemoattractant protein-1, eotaxin-3, and IL-6, which are
packaged into newly synthesized WPBs [9]. Because
WPBs are long-lived storage organelles with a turnover of
~ 24 h [10–12], endothelial cells will accumulate distinct
populations of granules that differ in their levels of cotar-
geted WPB cargo [9,13]. Whether the degree of inclusion
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of cotargeted WPB cargo reflects the endothelial activa-
tion state at the moment when the WPB was synthesized,
or whether this is a result of stochastic variation follow-
ing gradual redistribution of contents over the WPB pop-
ulation through content intermixing, as been reported for
other long-lived organelles such as lysosomes [14], is cur-
rently unclear. Interestingly, it has been suggested that
subsets of granules can be subject to differential exocyto-
sis [15], although the mechanism behind this differential
release remains elusive.
The endothelial secretory pathway
VWF secretion from endothelial cells occurs via three
main routes: constitutive secretion and basal secretion,
both of which occur in the absence of stimulation, and
regulated secretion of WPBs in response to endothelial
activation (Fig. 2). Following its journey through the
early secretory pathway, VWF undergoes a sorting step
at the level of the trans-Golgi network (TGN): low molec-
ular weight (LMW) VWF multimers enter the constitutive
secretory pathway in small short-lived anterograde carri-
ers, which are immediately released at the plasma mem-
brane [16]. High molecular weight (HMW) VWF
multimers enter the storage pathway by condensing into
tubules, which are packaged in nascent WPBs that bud
off the TGN [17]. This compartment constitutes the relea-
sable pool of HMW VWF that is secreted upon secreta-
gogue stimulation. The proportion of VWF that is sorted
into either direction has long been a matter of debate,
partly because previous studies considered only constitu-
tive and regulated secretion [16,18]. Careful kinetic moni-
toring of VWF trafficking has revealed that the storage
pathway is also responsible for the majority of
unstimulated VWF release through basal secretion [12].
This most likely reflects gradual, stochastic turnover of
WPBs, as VWF retention in this pathway correlates with
the reported half-life of these granules [10,12]. It suggests
that the secretory machinery of WPBs at baseline is
already in a certain degree of readiness that supports low-
level, spontaneous release. It also reconciles earlier and
recent observations that the bulk of VWF released by
resting endothelial cells is of a high multimeric nature
[18,19].
Apart from the degree of multimerization, another dis-
tinction between the constitutive and basal/stimulated
secretion pathways can be made on the basis of the polar-
ity of release. In vivo, the apical side of the endothelial
cells faces the vascular lumen, which results in VWF
secretion directly into the circulation. VWF unfurls and
assembles into ultralarge VWF strings that can be up to
several millimeters in length. Entanglement of several of
these strings leads to the formation of spiderweb-like net-
works that function as adhesive platforms for platelets
[20]. In this way, VWF strings act as polymeric force sen-
sors that, upon flow, expose a shear-dependent binding
site for platelet glycoprotein Ib [4]. Basolaterally released
VWF is deposited in the subendothelial matrix, where it
mediates platelet adhesion when the matrix is exposed fol-
lowing damage to the vessel wall, either directly or via
self-association with plasma VWF [21,22]. Over three dec-
ades ago, the idea had already arisen that secretion of
such functionally distinct pools of VWF may differ in
polarity, but previous studies addressing the polarity of
endothelial VWF release remained inconclusive because
they did not consider the contribution of spontaneous
release of regulated secretory cargo via the basal route
[23,24]. A recent study has now convincingly shown that
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Fig. 1. Weibel–Palade bodies (WPBs), secretory organelles of the endothelium. (A) Endothelial cells containing characteristic elongated WPBs
visualized by von Willebrand factor (VWF) immunostaining. (B) WPB ultrastructure, with a longitudinal section (left) showing internal striations,
and a cross-section (right) showing bundles, which represent densely packed VWF tubules. (C) Cartoon representation of WPB cargo. Ang-2,
angiopoietin-2; Eo-3, eotaxin-3; GROa, growth regulated oncogene a; IGFBP7, insulin-like growth factor-binding protein 7; IL-6, interleukin-6;
IL-8, interleukin-8; MCP-1, monocyte chemoattractant protein-1; OPG, osteoprotegerin.
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constitutive release of LMW VWF mainly occurs basolat-
erally, whereas basal and stimulated release of HMW
VWF from WPBs primarily occur at the apical face [19].
Stimuli and signaling cascades
WPB exocytosis is triggered by a wide range of physiolog-
ical (stress hormones, e.g. epinephrine; proteases, e.g.
thrombin; biogenic amines, e.g. histamine and 5-hydroxy-
tryptamine; and shear stress) and pathological (e.g. bacte-
rial toxins) signals (reviewed in [6]) that use Ca2+ or
cAMP as second messengers (Fig. 3). As part of an inte-
grated response to vascular injury, Ca2+-mediated secret-
agogues such as histamine and thrombin locally promote
a prothrombotic, proinflammatory state by instanta-
neously causing release of large quantities of VWF and
other WPB constituents, while simultaneously increasing
endothelial permeability and vascular tone [25,26]. In con-
trast, cAMP-mediated stimuli such as epinephrine and
vasopressin act systemically, increase endothelial barrier
function, and, when applied to cultured endothelial cells,
induce a slow but sustained release of WPBs [27–30]. This
pathway can be clinically exploited to correct prolonged
bleeding times in patients with mild hemophilia A or
VWD through administration of the vasopressin analog
DDAVP, which mobilizes VWF from its endothelial
stores following activation of vasopressin-2 receptor
(V2R) [28,31]. Despite their distinct kinetic and physio-
logical profiles, Ca2+-dependent and cAMP-dependent
pathways converge at the same effector pathways, which
control actin remodeling and tethering and fusion of
WPBs, albeit in some cases with different outcomes
(Fig. 3).
Increases in the intracellular free Ca2+ concentration
([Ca2+]i) occur after activation of phospholipase C (PLC)
by ligand-bound G-protein-coupled receptors (GPCRs)
[32]. Dose-dependent, subsecond release of WPBs in
response to ionophores or caged Ca2+ implies that sus-
tained elevation of [Ca2+]i is a sufficient transduction sig-
nal to drive WPB fusion independently from additional
receptor-triggered signaling [26,33]. In nearly every regu-
lated secretory system, a vesicle-associated Ca2+ sensor is
responsible for coupling transient elevations in [Ca2+]i to
the soluble N-ethylmaleimide-sensitive factor attachment
protein receptor (SNARE) fusion machinery, but, so far,
such a WPB-localized Ca2+ sensor has not been identified
[34]. However, a number of other Ca2+-sensing mecha-
nisms have been reported to couple cytosolic Ca2+ to the
endothelial exocytotic response. When Ca2+ is associated
with the Ca2+-sensor calmodulin (CaM), the Ca2+–CaM
complex binds to the N-terminus of the guanine nucleo-
tide exchange factor (GEF) RalGDS, thereby unleashing
its GEF activity towards the small GTPase RalA [35].
Activated RalA most likely coordinates a tethering step
by promoting Arf6-dependent phospholipase D1 (PLD1)
activity [36]. Local modification of phospholipids by
PLD1 generates plasma membrane microdomains that
recruit the Ca2+-binding and phospholipid-binding
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Fig. 2. The endothelial secretory pathway. von Willebrand factor (VWF) secretion occurs via three pathways: (i) constitutive secretion of low
molecular weight VWF, which is primarily released at the basolateral side of the endothelium; and (ii) basal and (iii) regulated secretion of high
molecular weight VWF from Weibel–Palade bodies (WPBs), which is primarily directed towards the apical surface. From the large number of
WPBs that undergo exocytosis upon stimulated release, ultralarge VWF (UL-VWF) multimers emerge that assemble into VWF strings on the
apical side of the endothelium.
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AnxA2–S100A10 complex, which, in its turn, links WPBs
to membrane fusion sites through the WPB-localized teth-
ering factor Munc13-4 [37–39]. Ca2+-mediated VWF
secretion is also dependent on rapid changes in the actin
cytoskeleton that lead to the formation of parallel stress
fibers, a process that is primarily regulated by GTPases
of the Rho family [29,40,41].
Triggering of the GPCR-coupled V2R and b2-adrener-
gic receptors activates cAMP-dependent protein kinase A
(PKA) after conversion of ATP to cAMP [27,28]. PKA is
critically involved in VWF secretion by activating a num-
ber of effector pathways [42], such as tethering of WPBs
through the RalGDS–RalA pathway and the AnxA2–
S100A10 tethering complex [30,35,38], and via phospho-
rylation of zyxin during contractile ring assembly [43].
During cAMP-mediated stimulation, a subset of WPBs
avoid release by clustering together around the micro-
tubule organizing center, as a result of dynein–dynactin-
dependent retrograde transport activated by PKA [42,44].
Whether this is a stochastic process that serves to limit
the secretory response or whether these WPBs represent a
specific subset of granules that are actively set aside, e.g.
according to their recruited membrane components, state
of maturation, or localization [15], is still unclear. The
exchange protein that is directly activated by cAMP is
also activated during cAMP-mediated WPB release, and
catalyzes the activation of the small GTPase Rap1
[45,46]. Via a complex of its downstream effectors phos-
phatidylinositol 3-kinase and the Rac exchange factor
PREX1, activated Rap1, in its turn, promotes activation
of the Rho GTPase Rac1 [47]. The Rap1–Rac1 pathway
is thought to promote secretion by rearranging actin into
thin cortical bundles in close apposition to the plasma
membrane and/or by regulating the formation or contrac-
tility of actin on the fusing WPB membrane [43].
Protein kinase C (PKC) is a key signaling mediator for
a number of endothelial agonists that trigger secretion of
VWF. Phorbol esters, such as phorbol 12-myristate 13-
acetate (PMA), are potent (non-physiological) stimulators
of VWF secretion that directly activate PKC by mimick-
ing the action of diacylglycerol [25]. Histamine, vascular
endothelial growth factor (VEGF) and Shiga toxin 1B
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Fig. 3. Signaling cascades in Weibel–Palade body (WPB) exocytosis. Ca2+-mediated and cAMP-mediated secretagogues that trigger WPB exo-
cytosis use distinct and common signaling circuits that converge at effector pathways that control anchoring, tethering, vesicle fusion, and actin
contractility. AC, adenylyl cyclase; ATP, adenosine triphosphate; CaM, calmodulin; [Ca2+]i, intracellular free Ca
2+ concentration; DAG, dia-
cylglycerol; EPAC, exchange protein that is directly activated by cAMP; Gb3, ceramide trihexoside; H1R, histamine H1 receptor; IP3, inositol
1,4,5-triphosphate; PAR1, protease-activated receptor 1; PI3K, phosphatidylinositol 3-kinase; PIPa, phosphatidylinositol 4,5-bisphosphate;
PIP2, phosphatidylinositol 4,5-bisphosphate; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; PLD1, phospholipase D1;
SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor; Stx1B, Shiga toxin 1B; V2F, vasopressin-2 receptor; VEGF,
vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2; b2-AR, b2-adrenergic receptor.
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(Stx1B) elevate [Ca2+]i in a PLC-dependent manner, and
simultaneously either signal through the Ca2+-indepen-
dent PKCd (VEGF and histamine) or utilize the Ca2+-
dependent PKCa (Stx1B and histamine) [32,48–51].
Among its targets are components of the SNARE
machinery, the assembly of which is partly regulated
through PKC-dependent phosphorylation events [52].
Nevertheless, several ambiguities remain that suggest that
PKC is not always essential for VWF secretion. Both
VEGF and histamine activate PKCd; however, broad-
range PKC inhibition or specific depletion of PKCd sig-
nificantly reduced secretory responses after VEGF but
not after histamine administration [48]. PKCa is activated
by Stx1B as well as by histamine, but is only essential for
Stx1B-induced release; inhibition of PKCa did not block
histamine-induced VWF secretion and, in some studies,
even enhanced it [48,51,53–55]. Paradoxically, three inde-
pendent studies showed that blocking Ca2+ signaling,
which entirely abolishes VWF release induced by both
histamine and PKCa-dependent Stx1B, was not sufficient
to fully inhibit VEGF-induced VWF secretion
[32,48,50,53]. The difference in requirement for PKC and
Ca2+ raises intriguing questions about how common sig-
naling pathways activated by different agonists are differ-
entially utilized and integrated to control secretion.
Exocytotic machinery of WPBs
After emerging from the TGN, immature WPBs initially
are secretion-incompetent because they have yet to
acquire (parts of) the exocytotic machinery [56]. In a mat-
uration-dependent manner, WPBs recruit several GTPases
of the Rab family, including Rab27A, several Rab3 iso-
forms, and Rab15 [37,56–58]. Rab GTPases are molecular
switches that cycle between a GDP-bound ‘off’ state and
a membrane-associated, GTP-bound ‘on’ state, and gener-
ally contribute to defining organelle identity [59]. In their
active GTP-bound state, the Rabs are responsible for the
subsequent recruitment of a set of effector proteins
(MyRIP, Munc13-4, and Slp4-a) to the WPB. This pro-
cess correlates with the acquisition of secretion compe-
tence [56], and enables WPBs to interact with the
cytoskeleton and/or plasma membrane (Fig. 4) [56,58,60].
MyRIP is a Rab27A-specific effector that binds actin,
directly and via the actin motor protein myosin Va, and
tethers WPBs to the actin cytoskeleton in the cell periph-
ery [41,60,61]. The actin cytoskeleton plays opposing roles
in the release of WPBs. On the one hand, it is necessary
for peripheral distribution of WPBs, which is important
for releasability and depends on myosin IIa [62]. On the
other hand, actin acts as a barrier [29,40], and, by
anchoring WPBs to the actin cytoskeleton, MyRIP acts
as a brake during exocytosis [41,56,60]. Munc13-4 binds
both Rab27A and Rab15, and promotes exocytosis by
tethering WPBs to release sites on the plasma membrane,
which contain the annexin A2–S100A10 complex [39,58].
Slp4-a interacts with Rab3 isoforms and Rab27A, in an
activity-insensitive manner with the latter, and promotes
WPB exocytosis [56] by providing the link between the
WPB and members of the SNARE complex [63]. From
this all, it becomes clear that, during acquisition of secre-
tion competence, WPBs recruit a cocktail of Rabs and
Rab effectors that individually perform opposing func-
tions during secretion. Upon exocytosis, they engage in a
tug of war in which the balance of effectors, their levels
of activation by upstream signaling events and the effi-
cacy of their downstream mechanisms decide the proba-
bility of release [56].
In the final phase of exocytosis, the WPB fuses with
the plasma membrane; this is catalyzed by a ternary com-
plex of SNARE proteins that are positioned on the two
opposing membranes. SNARE proteins can be function-
ally classified as t-SNAREs, which are found on the tar-
get membrane, and v-SNAREs, which are found on the
donor/vesicle membrane. The exocytotic SNARE complex
consists of a v-SNARE of the vesicle-associated mem-
brane protein (VAMP) family on the donor (i.e. WPB)
membrane, and two t-SNAREs (one SNARE helix from
a syntaxin, and two SNARE helices from a SNAP25
homolog) on the acceptor (i.e. plasma) membrane
(Fig. 5). Together, they assemble into a four-helix bundle
that, when it rolls up, brings donor and acceptor mem-
branes together in a zipper-like motion, thereby largely
overcoming the energy barrier that normally prevents
fusion of membranes. WPBs contain two v-SNAREs,
VAMP3 and VAMP8, of which only VAMP3 has so far
been shown to support stimulus-induced WPB release
[64,65]. t-SNAREs that take part in WPB release include
the SNAP25 homolog SNAP23, syntaxin-3, syntaxin-4,
and most likely also syntaxin-2 [52,63,66,67]. Owing to
their promiscuous nature, various combinations of these
SNAREs exist: in endothelial cells, syntaxin-4 engages
with SNAP23 and VAMP3 or VAMP8 [65,67], and syn-
taxin-3 primarily interacts with VAMP8 and SNAP23
[67]. The SNARE partners of syntaxin-2 are still
unknown. This suggests that endothelial cells can employ
at least three (syntaxin-4–SNAP23–VAMP3, syntaxin-4–
SNAP23–VAMP8, and syntaxin-3–SNAP23–VAMP8)
and possibly more distinct SNARE complexes for release
of WPBs. Interestingly, whereas syntaxin-4 is localized on
the plasma membrane, syntaxin-3 is found on WPBs [67],
suggesting that, in certain cases, WPBs can also function
as the acceptor compartment during fusion.
The formation of SNARE complexes is controlled by
syntaxin-binding proteins (STXBPs), several of which
take part in WPB release. The Slp4-a interactor STXBP1
promotes VWF secretion and interacts with syntaxin-2 or
syntaxin-3 [63], potentially controlling two separate
downstream mechanisms for exocytosis. Munc18c (also
known as STXBP3) controls the assembly of syntaxin-
4-containing SNARE complexes. Depending on a (de)
phosphorylation switch controlled by PKCa and protein
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis
and Haemostasis.
Regulation of WPB exocytosis 5
phosphatase 2B, phosphorylated Munc18c releases its
grip on syntaxin-4 and allows the latter to engage with
VAMP3 [52,68]. STXBP5 was initially implicated in the
WPB exocytotic machinery as a genetic modifier of circu-
lating VWF: a polymorphism encoding the non-synon-
ymous N436S substitution in STXBP5 is linked to lower
VWF plasma levels [69]. In endothelial cells, STXBP5 is a
negative regulator of WPB release, and interacts with syn-
taxin-4 but not with SNAP23 [70]. Possibly, the C-term-
inal VAMP-like domain acts as a decoy for syntaxin-4,
producing a non-fusogenic dead end, thereby lowering
the number of syntaxin-4-containing SNARE complexes
that can support exocytosis. Interestingly, the N436S vari-
ant of STXBP5 attenuates VWF secretion in endothelial
cells [70], although the mechanism through which this
substitution inhibits release is still unclear. The SNARE
machinery is therefore highly dynamic and, according to
its configuration, may promote or attenuate secretion, but
exactly how all of these individual components together
orchestrate WPB release remains unclear. Moreover, it
raises the question of why endothelial cells utilize so
many different SNARE complexes for exocytosis of the
same secretory organelle.
Secretory modes of WPB exocytosis
Several different modes of stimulus-induced WPB exocy-
tosis have been reported (Fig. 5A). Initially, a lipidic
fusion pore is formed at the interface of vesicle and
plasma membrane that establishes an aqueous channel
between the WPB lumen and the extracellular space [71].
Recordings of fusion pore dynamics of serotonin-loaded
WPBs by he use of amperometry revealed that this
transient structure exists for only a limited time (usually
< 200 ms) before it rapidly expands within tens of mil-
liseconds [72]. With its pore expanded fully, the WPB
undergoes full fusion, resulting in the delivery of soluble
granule cargo into the lumen and collapse of the vesicle
membrane together with its associated membrane compo-
nents into the plasma membrane [26,73]. In a subset of
cases, the WPB fusion pore does not expand fully, but
the pore lingers in a restricted state for some seconds
before closing prematurely. The restricted diameter of the
pore during this ‘lingering’ mode of fusion, so-called lin-
gering-kiss exocytosis, acts as a molecular size filter: small
cargoes, such as chemokines or the integral membrane
protein CD63, are able to traverse the narrow pore that
prevents the passage of larger cargo proteins such as
VWF, VWF propeptide, and P-selectin. After resealing of
the unexpanded fusion pore, these proteins are selectively
retained in spherical WPBs, which probably owe their
rounded morphology and the disruption of the orderly
bundling of VWF tubules to the hydration of their
paracrystalline interior [74].
Apart from these heterotypic fusion modes (fusion
between different compartments, i.e. WPB and plasma
membrane), homotypic fusion modes (i.e. WPB–WPB)
have also been described. During compound fusion, sev-
eral individual WPBs coalesce intracellularly prior to
release, and then collectively undergo exocytosis as a sin-
gle entity. The first evidence for this mode of fusion in
endothelial cells was provided by measurements of mem-
brane capacitance, which is proportional to cell surface
area, stepwise increases of which are attributable to the
addition of membrane during the fusion of secretory
organelles. A significant proportion of discrete membrane
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Fig. 4. The Weibel–Palade body (WPB) exocytotic machinery. Rab effector complexes mediate anchoring of WPBs to the cytoskeleton, tether-
ing to the plasma membrane, and interactions with the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) fusion
machinery. The Rab27A–MyRIP–myosin Va complex anchors WPBs to the actin cytoskeleton. Munc13-4 can be recruited by Rab GTPase-
dependent (Rab15/Rab27A) or by Rab-independent mechanisms, and tethers WPBs to membrane fusion sites via the annexin A2–S100A10
complex. The Rab27A–Slp4-a complex docks WPBs and forms the link between the WPB and the SNARE complex via members of the syn-
taxin-binding protein (STXBP) family. VAMP, vesicle-associated membrane protein.
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capacitance increases observed after evoking of WPB exo-
cytosis with high levels of [Ca2+]i were too large to be
accounted for by the fusion of a single WPB, and could
only be explained by fusion of an accumulated structure
made up of several WPBs [33]. Morphological studies of
such intermediate structures have shown that they consist
of enlarged, rounded structures, termed secretory pods,
which contain disordered VWF tubules [75]. Secretory
pods are prominent features following extended stimula-
tion with PMA, but the occurrence of similar structures
has also been demonstrated in vivo in response to acti-
vated FX or histamine in toads and rats, respectively
[76,77]. Despite the loss of tubular organization of VWF
multimers in the spherical secretory pods, VWF strings
can eventually emerge from the extruded material [78].
Finally, by monitoring of the redistribution of EGFP–
A
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v-SNAREs
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Fig. 5. Secretory modes of Weibel–Palade body (WPB) exocytosis. (A) Cartoon of a WPB with WPB-localized v-SNAREs (blue) engaging with
target membrane-localized t-SNAREs (pink and green), thereby bringing together donor and acceptor membranes. Top: a narrow fusion pore
is formed that permits release of small cargo. Lingering-kiss fusion resulting from premature closure of the fusion pore results in large cargo
(von Willebrand factor [VWF]) being retained in a collapsed granule, whereas expansion of the fusion pore results in full fusion followed by
explosive release of ultralarge VWF strings. Top right: compound fusion of WPBs, possibly including lingering-kiss end-products, leads to the
formation of an enlarged secretory pod that eventually undergoes fusion at the plasma membrane. Bottom left: cumulative or sequential fusion,
in which a primary granule undergoes fusion at the plasma membrane, which is followed by secondary fusion events in the postfusion WPB,
ultimately leading to extensive, ginger root-like fusion structures. (B) Two models of SNARE-mediated cumulative fusion. (Bi) Sequential
fusion events are supported by cognate SNARE assemblies on individual, prefusion WPBs. (Bii) Cumulative release is supported by rapid
membrane mixing, recruiting plasma membrane SNARE components into the postfusion WPB. SNARE, soluble N-ethylmaleimide-sensitive
factor attachment protein receptor; VAMP, vesicle-associated membrane protein.
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CD63 through the membranes of fusing granules, a
related but mechanistically distinct mode of homotypic
WPB fusion, termed sequential or cumulative exocytosis,
was observed [79]. In this mode, a postfusion WPB is
used as a membrane fusion site for subsequent cumulative
fusion of additional WPBs, culminating in the ginger
root-like fusion structures that were observed in ultra-
structural studies [76,80].
A number of questions remain. First, what is the
molecular basis for all of these different release mecha-
nisms? The specificity of membrane fusion during exocy-
tosis is mediated by the interaction of SNAREs on
secretory organelles with their cognate SNAREs on the
target membrane. In cases of homotypic fusion, such as
during secretory pod or cumulative exocytosis, this would
require the formation of a trans-complex consisting of v-
SNAREs and t-SNAREs that are positioned on opposing
WPBs (Fig. 5Bi). Within the extensive set of SNAREs
that have, in one way or another, been implicated in the
WPB exocytotic machinery, the pair composed of
VAMP8 and syntaxin-3 has been shown to sustain homo-
typic fusion modes in cells in which both were found on
secretory organelles [65,67,81,82]. An alternative explana-
tion is offered by the rapid transfer of plasma membrane
proteins to fusing WPBs through membrane mixing, such
as was observed for Rab35 [79]. Possibly, this confers
plasma membrane identity to the postfusion WPB, includ-
ing the acquisition of components of the fusion machin-
ery from the plasma membrane, such as the cognate
SNAREs for WPB-localized VAMPs (Fig. 5Bii). This
also raises the possibility that secretory pods represent an
intermediate state during cumulative fusion into WPBs
that have previously undergone lingering-kiss exocytosis.
Second, what is the use of all these distinct modes of
exocytosis? Indirect or incomplete fusion modes are, in
certain cases, energetically favorable. Homotypic fusion
modes can serve to concentrate cargo release at hotspots
when access to fusion sites on the membrane becomes
limiting. It may also augment the secretory response by
providing indirect access to the plasma membrane to a
pool of WPBs situated deeper into the cytoplasm [80].
Lingering-kiss fusion not only saves vesicle reformation
and retrieval of vesicle membrane proteins, but may also
help in preserving a delicate balance between endocytosis
and exocytosis by limiting membrane expenditure. Exocy-
tosis–endocytosis coupling is pertinent to the choice of
secretory mode, as pharmacological blocking of compen-
satory endocytosis resulted in a shift from full fusion
towards cumulative exocytosis, possibly because of the
inability to retrieve membrane components from the post-
fusion WPBs [80]. Distinct fusion modes also allow the
endothelium to fine-tune its secretory response to specific
vascular conditions: lingering-kiss fusion releases only a
subset of molecules, such as chemokines, whereas pro-
thrombotic cargo is not released [74]. Postfusion entangle-
ment of VWF tubules in both compound and cumulative
fusion structures does not preclude the eventual forma-
tion of VWF strings, but results in shorter strings when
cumulative fusion is promoted [78,80].
Content expulsion
Secretory cargo expulsion is dependent on lateral tension
in the plasma membrane; relaxation of this tension
through the addition of new membrane from fusing gran-
ules opens the fusion pore and provides a force to drive
secretory cargo out; this is followed by full collapse of the
vesicle into the plasma membrane [83]. However, the
near-solid VWF paracrystal presents a significant barrier
to release, as its enormous size and state will naturally
resist discharge and membrane collapse. Recent studies
have shown that endothelial cells, depending on their type
of activation, can utilize fundamentally different modes of
secretory content expulsion.
The rapid process of content expulsion during Ca2+-
mediated full fusion of WPBs bears the hallmarks of a
jack-in-the-box mechanism that is often observed when
condensed, polyionic molecules such as VWF need to
undergo a phase transition before release [84]. Exchange
of ions and entry of water molecules into the vesicle inte-
rior through the stalk-shaped fusion pore leads to hydra-
tion of the vesicle core and rapid neutralization of the
acidic milieu of the WPB [26]. Dissolution of the proton
gradient and other cationic species such as Ca2+ that are
crucial for the condensed tubular packing of VWF [85,86]
will result in loss of shielding of negative charges in
VWF. The consequential charge repulsion within and
between VWF multimers leads to decondensation of
cargo, as shown by the swelling of the granule and
increased separation between VWF tubules [71]. This is
followed by an explosive discharge of ultralarge VWF
multimers and other cargo on a subsecond timescale, con-
sistent with a mechanism in which VWF tubules act as
electrostatic springs [26,73,87,88].
An alternative mechanism of VWF expulsion has been
observed in response to Ca2+-independent secretagogues,
such as cAMP-mediated agonists or phorbol esters. Prior
to fusion, local rearrangements of cortical actin lead to
the formation of actin frameworks that appear to encage
WPBs. The formation of such frameworks is dependent
on the tension-sensitive focal adhesion protein zyxin fol-
lowing its phosphorylation by PKA, and positions WPBs
close to the membrane [43]. Then, shortly after opening
of the fusion pore, an actomyosin ring is assembled coat-
ing the distal end of the fusing granule, a process that
involves de novo actin polymerization [43,89]. Inhibition
of the myosin IIa-dependent contractility of the acto-
myosin ring prevented VWF release from fusing WPBs,
while not affecting the secretory fate of P-selectin [89]
(but not in [62]), leading to the hypothesis that contrac-
tion of such rings provides the necessary physical force to
squeeze VWF out of the fusing granule. It is currently
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unclear what initiates actomyosin ring formation on the
postfusion WPB, but the involvement of the tension sen-
sor zyxin [43] suggests that changes in local (membrane)
tension, such as on a swelling granule, may be an impor-
tant factor in this process. Actomyosin ring contractility
is regulated by phosphorylation of myosin IIa, which has
been shown to involve zyxin-dependent recruitment of
casein kinase II [62]. Interestingly, zyxin depletion did not
impair VWF release by thrombin or histamine, which is
consistent with the observation that actomyosin rings do
not play an important role in expulsion of VWF during
Ca2+-mediated WPB exocytosis [43,87].
WPBs in health and disease
Circulating levels of VWF vary widely across the human
population [90]. The clinical manifestations at the far
ends of this distribution highlight the pivotal role that
VWF plays in vascular health. Low levels of plasma
VWF lead to bleeding, such as in the inherited bleeding
disorder VWD [5]. In some cases, this is the result of
mutations in VWF that lead to altered WPB morphology
and decreased releasability, such as is evident in VWD
blood outgrowth endothelial cells [91]. Increased levels of
circulating VWF are associated with cardiovascular mor-
bidities, such as coronary heart disease, ischemic stroke,
and venous and arterial thrombosis [92,93], which are
pathologies for which the risks are reduced in VWD
patients [94]. The variation in VWF plasma levels across
the population is largely genetically determined [95]. Pop-
ulation-based linkage analyses in healthy individuals have
identified a number of genetic loci that are associated
with VWF levels, including the ABO locus and the clear-
ance receptors CLEC4M and STAB2, but also genes
encoding several components of the SNARE machinery
(STX2 and STXBP5) [69,96]. One of the SNPs in
STXBP5 that was linked with higher VWF levels is also
associated with venous thrombosis [97]. Variants in both
STX2 and STXBP5 are also associated with VWF levels
and disease severity in VWD patients [98]. Together, these
findings show that SNARE-mediated secretion from
WPBs is an important determinant of VWF plasma
levels. This fits with the current consensus that most cir-
culating VWF, which primarily consists of high-multimer
VWF, originates from the storage pathway rather than
from constitutive secretion [12,18,19]. Whether this arises
from the basal compartment or stimulated compartment
may be less evident. Several of the Rab-associated and
SNARE-associated regulators of stimulated WPB exocy-
tosis also affect the basal secretion of VWF [56,63,67],
suggesting that the same SNARE fusion machinery is also
responsible for basal release. Basal secretion accounts for
the bulk of VWF that endothelial cells produce and
release over time. How reflective this is of the situation
in vivo, in which some areas of the vasculature may be
under the continuous influence of low-level stimulation by
hormones such as epinephrine or vasopressin, is unclear.
However, on the basis of extrapolation of the ratio of
basal to stimulated release from cultured endothelial cells,
the area of vascular bed that needs to be to be maximally
activated at any given time to match what is secreted
basally makes it unlikely that stimulated release con-
tributes significantly to steady-state VWF levels [19].
Another pathology that may arise from disturbed
release from WPBs is angiodysplasia, which is a common
complication in VWD patients that causes recurrent gas-
trointestinal bleeding through small vascular malforma-
tions in the gut. Recent studies have shown that VWF
regulates angiogenesis, extracellularly by controlling the
cell surface expression of aVb3 integrin and/or indirectly
by influencing the release of one of its WPB coresidents,
the angiogenic mediator Ang-2 [99]. In the absence of its
storage compartment, such as occurs in severe type 3
VWD, Ang-2 is secreted constitutively, promoting vessel
destabilization. Apart from Ang-2, a number of other
angiogenic mediators, such as insulin-like growth factor-
binding protein 7, galectin-1, and galectin-3, are found in
WPBs [7,100], and may be subject to similar dysregulated
release in the absence of VWF, potentially further con-
tributing to pathological angiogenesis.
Conclusions and future directions
Endothelial cells control secretion from their WPBs by
using a remarkably complex exocytotic machinery, the
outlines of which are now starting to become clear. How-
ever, our knowledge of the exact composition of this
machinery is incomplete and, importantly, we are still a
long way from understanding how all of these compo-
nents are able to direct the different modes of WPB
fusion. Also, we currently do not understand how expan-
sion of the fusion pore is regulated or what drives content
expulsion in response to different endothelial activation
states. To obtain a deeper understanding of these pro-
cesses, we will need to determine the changes to the char-
acteristic ultrastructure of WPBs during fusion and
content expulsion, and to link these changes to individual
components of the exocytotic machinery. Understanding
the mechanism and purpose of the endothelium’s ability
to fine-tune its secretory response to vascular events
would potentially allow us to exploit this mechanism for
therapeutic benefit in the treatment of hematological and
cardiovascular diseases.
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